Analysis of MDM2 amplification in 43 endometrial stromal tumors: A potential diagnostic pitfall

J. Kenneth Schoolmeester, Andrew P. Sciallis, Patricia T Greipp, Jennelle C. Hodge, Paola Dal Cin, Gary Keeney, Marisa R. Nucci

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

MDM2 amplification is known to occur in a variety of neoplasms and its detection by fluorescence in situ hybridization is helpful in distinguishing welldifferentiated and dedifferentated liposarcoma from classic lipoma. We recently evaluated a mesenteric mass initially diagnosed as dedifferentiated liposarcoma, largely due to the neoplasm's myxoid morphology and MDM2 expression by immunohistochemistry, from a 46-yr-old woman with a history of uterine low-grade endometrial stromal sarcoma (LG-ESS) with a JAZF1 rearrangement. Our workup of the mesenteric mass revealed a JAZF1 rearrangement and a revised diagnosis of metastatic LG-ESS with myxoid change was rendered. Retrospective testing of the mesenteric mass was negative for MDM2 amplification, an uncommon, but known diagnostic pitfall in MDM2 expression by immunohistochemistry. As MDM2 amplification is not specific for the diagnosis of liposarcoma, we investigated its occurrence in 43 cases of endometrial stromal tumors: 14 uterine LG-ESS, 11 metastatic or recurrent uterine LGESS, 8 undifferentiated uterine sarcomas, 5 endometrial stromal nodules, and 4 highgrade ESS with YHWAE rearrangement. In addition, 40 of the 43 cases had previously undergone fluorescence in situ hybridization analysis of JAZF1, PHF1, and YHWAE. Two of the 43 cases (5%) had MDM2 amplification: one was a uterine LG-ESS (JAZF1 rearrangement) and the other was a undifferentiated uterine sarcoma (polysomy intact JAZF1, PHF1, and YHWAE), both metastatic to the lung. Both cases positive for MDM2 amplification showed MDM2 expression by immunohistochemistry. At last follow-up, both patients had died of disease (19 and 60 mo). Our study is the first to demonstrate MDM2 amplification in endometrial stromal tumor. Awareness of MDM2 amplification in endometrial stromal tumor is critical; particularly in locations more common to liposarcoma, to avoid diagnostic errors.

Original languageEnglish (US)
Pages (from-to)576-583
Number of pages8
JournalInternational Journal of Gynecological Pathology
Volume34
Issue number6
DOIs
StatePublished - 2015

Fingerprint

Endometrial Stromal Tumors
Liposarcoma
Immunohistochemistry
Fluorescence In Situ Hybridization
Endometrial Stromal Sarcoma
Lipoma
Diagnostic Errors
Sarcoma
Neoplasms
Lung

Keywords

  • Endometrial stromal tumor
  • Liposarcoma
  • MDM2

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Obstetrics and Gynecology

Cite this

Analysis of MDM2 amplification in 43 endometrial stromal tumors : A potential diagnostic pitfall. / Schoolmeester, J. Kenneth; Sciallis, Andrew P.; Greipp, Patricia T; Hodge, Jennelle C.; Cin, Paola Dal; Keeney, Gary; Nucci, Marisa R.

In: International Journal of Gynecological Pathology, Vol. 34, No. 6, 2015, p. 576-583.

Research output: Contribution to journalArticle

@article{a587d5e4bb7f499086ae67d4a0c9ebe6,
title = "Analysis of MDM2 amplification in 43 endometrial stromal tumors: A potential diagnostic pitfall",
abstract = "MDM2 amplification is known to occur in a variety of neoplasms and its detection by fluorescence in situ hybridization is helpful in distinguishing welldifferentiated and dedifferentated liposarcoma from classic lipoma. We recently evaluated a mesenteric mass initially diagnosed as dedifferentiated liposarcoma, largely due to the neoplasm's myxoid morphology and MDM2 expression by immunohistochemistry, from a 46-yr-old woman with a history of uterine low-grade endometrial stromal sarcoma (LG-ESS) with a JAZF1 rearrangement. Our workup of the mesenteric mass revealed a JAZF1 rearrangement and a revised diagnosis of metastatic LG-ESS with myxoid change was rendered. Retrospective testing of the mesenteric mass was negative for MDM2 amplification, an uncommon, but known diagnostic pitfall in MDM2 expression by immunohistochemistry. As MDM2 amplification is not specific for the diagnosis of liposarcoma, we investigated its occurrence in 43 cases of endometrial stromal tumors: 14 uterine LG-ESS, 11 metastatic or recurrent uterine LGESS, 8 undifferentiated uterine sarcomas, 5 endometrial stromal nodules, and 4 highgrade ESS with YHWAE rearrangement. In addition, 40 of the 43 cases had previously undergone fluorescence in situ hybridization analysis of JAZF1, PHF1, and YHWAE. Two of the 43 cases (5{\%}) had MDM2 amplification: one was a uterine LG-ESS (JAZF1 rearrangement) and the other was a undifferentiated uterine sarcoma (polysomy intact JAZF1, PHF1, and YHWAE), both metastatic to the lung. Both cases positive for MDM2 amplification showed MDM2 expression by immunohistochemistry. At last follow-up, both patients had died of disease (19 and 60 mo). Our study is the first to demonstrate MDM2 amplification in endometrial stromal tumor. Awareness of MDM2 amplification in endometrial stromal tumor is critical; particularly in locations more common to liposarcoma, to avoid diagnostic errors.",
keywords = "Endometrial stromal tumor, Liposarcoma, MDM2",
author = "Schoolmeester, {J. Kenneth} and Sciallis, {Andrew P.} and Greipp, {Patricia T} and Hodge, {Jennelle C.} and Cin, {Paola Dal} and Gary Keeney and Nucci, {Marisa R.}",
year = "2015",
doi = "10.1097/PGP.0000000000000187",
language = "English (US)",
volume = "34",
pages = "576--583",
journal = "International Journal of Gynecological Pathology",
issn = "0277-1691",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Analysis of MDM2 amplification in 43 endometrial stromal tumors

T2 - A potential diagnostic pitfall

AU - Schoolmeester, J. Kenneth

AU - Sciallis, Andrew P.

AU - Greipp, Patricia T

AU - Hodge, Jennelle C.

AU - Cin, Paola Dal

AU - Keeney, Gary

AU - Nucci, Marisa R.

PY - 2015

Y1 - 2015

N2 - MDM2 amplification is known to occur in a variety of neoplasms and its detection by fluorescence in situ hybridization is helpful in distinguishing welldifferentiated and dedifferentated liposarcoma from classic lipoma. We recently evaluated a mesenteric mass initially diagnosed as dedifferentiated liposarcoma, largely due to the neoplasm's myxoid morphology and MDM2 expression by immunohistochemistry, from a 46-yr-old woman with a history of uterine low-grade endometrial stromal sarcoma (LG-ESS) with a JAZF1 rearrangement. Our workup of the mesenteric mass revealed a JAZF1 rearrangement and a revised diagnosis of metastatic LG-ESS with myxoid change was rendered. Retrospective testing of the mesenteric mass was negative for MDM2 amplification, an uncommon, but known diagnostic pitfall in MDM2 expression by immunohistochemistry. As MDM2 amplification is not specific for the diagnosis of liposarcoma, we investigated its occurrence in 43 cases of endometrial stromal tumors: 14 uterine LG-ESS, 11 metastatic or recurrent uterine LGESS, 8 undifferentiated uterine sarcomas, 5 endometrial stromal nodules, and 4 highgrade ESS with YHWAE rearrangement. In addition, 40 of the 43 cases had previously undergone fluorescence in situ hybridization analysis of JAZF1, PHF1, and YHWAE. Two of the 43 cases (5%) had MDM2 amplification: one was a uterine LG-ESS (JAZF1 rearrangement) and the other was a undifferentiated uterine sarcoma (polysomy intact JAZF1, PHF1, and YHWAE), both metastatic to the lung. Both cases positive for MDM2 amplification showed MDM2 expression by immunohistochemistry. At last follow-up, both patients had died of disease (19 and 60 mo). Our study is the first to demonstrate MDM2 amplification in endometrial stromal tumor. Awareness of MDM2 amplification in endometrial stromal tumor is critical; particularly in locations more common to liposarcoma, to avoid diagnostic errors.

AB - MDM2 amplification is known to occur in a variety of neoplasms and its detection by fluorescence in situ hybridization is helpful in distinguishing welldifferentiated and dedifferentated liposarcoma from classic lipoma. We recently evaluated a mesenteric mass initially diagnosed as dedifferentiated liposarcoma, largely due to the neoplasm's myxoid morphology and MDM2 expression by immunohistochemistry, from a 46-yr-old woman with a history of uterine low-grade endometrial stromal sarcoma (LG-ESS) with a JAZF1 rearrangement. Our workup of the mesenteric mass revealed a JAZF1 rearrangement and a revised diagnosis of metastatic LG-ESS with myxoid change was rendered. Retrospective testing of the mesenteric mass was negative for MDM2 amplification, an uncommon, but known diagnostic pitfall in MDM2 expression by immunohistochemistry. As MDM2 amplification is not specific for the diagnosis of liposarcoma, we investigated its occurrence in 43 cases of endometrial stromal tumors: 14 uterine LG-ESS, 11 metastatic or recurrent uterine LGESS, 8 undifferentiated uterine sarcomas, 5 endometrial stromal nodules, and 4 highgrade ESS with YHWAE rearrangement. In addition, 40 of the 43 cases had previously undergone fluorescence in situ hybridization analysis of JAZF1, PHF1, and YHWAE. Two of the 43 cases (5%) had MDM2 amplification: one was a uterine LG-ESS (JAZF1 rearrangement) and the other was a undifferentiated uterine sarcoma (polysomy intact JAZF1, PHF1, and YHWAE), both metastatic to the lung. Both cases positive for MDM2 amplification showed MDM2 expression by immunohistochemistry. At last follow-up, both patients had died of disease (19 and 60 mo). Our study is the first to demonstrate MDM2 amplification in endometrial stromal tumor. Awareness of MDM2 amplification in endometrial stromal tumor is critical; particularly in locations more common to liposarcoma, to avoid diagnostic errors.

KW - Endometrial stromal tumor

KW - Liposarcoma

KW - MDM2

UR - http://www.scopus.com/inward/record.url?scp=84943606073&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943606073&partnerID=8YFLogxK

U2 - 10.1097/PGP.0000000000000187

DO - 10.1097/PGP.0000000000000187

M3 - Article

C2 - 26444253

AN - SCOPUS:84943606073

VL - 34

SP - 576

EP - 583

JO - International Journal of Gynecological Pathology

JF - International Journal of Gynecological Pathology

SN - 0277-1691

IS - 6

ER -